secwatch / observer
8-K filed November 10, 2025, 6:59 PM ET ticker SLVM CIK 0001856485
other material confidence high sentiment neutral materiality 0.65

Sylvamo adopts limited-duration rights plan after Atlas Holdings ends cooperation agreement

Sylvamo Corp

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Sylvamo Corp issued one preferred share purchase right for each share of common stock of common stock to stockholders of record as of November 20, 2025.

Security
common stock
Shares
one preferred share purchase right for each share of common stock
Purchaser
stockholders of record as of November 20, 2025
Exact text from the filing
On November 10, 2025, the board of directors (the “Board of Directors”) of Sylvamo Corporation (the “Company”) declared a dividend of one preferred share purchase right (a “Right”), payable on November 20, 2025, for each share of common stock, par value $1.00 per share, of the Company (the “Common Shares”) outstanding on November 20, 2025 (the “Record Date”) to the stockholders of record on that date.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Sylvamo Corp: Filed a Certificate of Designations designating Series B Preferred Stock in connection with the adoption of a Rights Agreement (effective 2025-11-10).

Change
charter amendment
Effective
2025-11-10
Exact text from the filing
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the adoption of the Rights Agreement, on November 10, 2025, the Company filed a Certificate of Designations designating Series B Preferred Stock with the Delaware Secretary of State.
View on SEC.gov

Browse all equity issuances →

Sylvamo Corp filing history →

Source: SEC EDGAR
accession 0001193125-25-274343
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.